Bio-Techne Corporation (TECH)

Market Cap	9.26B
Revenue (ttm)	1.22B
Net Income (ttm)	77.95M
Shares Out	155.69M
EPS (ttm)	0.49
PE Ratio	124.03
Forward PE	29.67
Dividend	$0.32 (0.53%)
Ex-Dividend Date	Aug 18, 2025

Volume	3,533,143
Open	54.40
Previous Close	61.10
Day's Range	54.20 - 61.12
52-Week Range	46.01 - 80.80
Beta	1.47
Analysts	Buy
Price Target	70.58 (+18.68%)
Earnings Date	Nov 5, 2025

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,100
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.

Analyst Summary

According to 13 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $70.58, which is an increase of 18.68% from the latest price.

Price Target

$70.58

(18.68% upside)

Analyst Consensus: Buy